Khalid B Beshir

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/52152/publications.pdf

Version: 2024-02-01

36 papers	1,369 citations	430874 18 h-index	361022 35 g-index
39 all docs	39 docs citations	39 times ranked	1781 citing authors

#	Article	IF	Citations
1	Deletions of the Plasmodium falciparum histidine-rich protein 2/3 genes are common in field isolates from north-eastern Tanzania. Scientific Reports, 2022, 12, 5802.	3.3	9
2	Screening strategies and laboratory assays to support Plasmodium falciparum histidine-rich protein deletion surveillance: where we are and what is needed. Malaria Journal, 2022, 21, .	2.3	8
3	Antimalarial drug resistance markers in human immunodeficiency virus (HIV)-positive and HIV-negative adults with asymptomatic malaria infections in Port Harcourt, Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 531-537.	1.8	3
4	Failure of rapid diagnostic tests in Plasmodium falciparum malaria cases among travelers to the UK and Ireland: Identification and characterisation of the parasites. International Journal of Infectious Diseases, 2021, 108, 137-144.	3.3	12
5	Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents and Chemotherapy, 2021, 65, e0087321.	3.2	7
6	Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet, The, 2020, 396, 1829-1840.	13.7	128
7	Plasmodium falciparum isolate with histidine-rich protein 2 gene deletion from Nyala City, Western Sudan. Scientific Reports, 2020, 10, 12822.	3.3	6
8	Recurrence of Plasmodium malariae and P. falciparum Following Treatment of Uncomplicated Malaria in North Sumatera With Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine. Open Forum Infectious Diseases, 2020, 7, ofaa116.	0.9	16
9	Plasmodium falciparum Isolates Carrying pf k13 Polymorphisms Harbor the SVMNT Allele of pfcrt in Northwestern Indonesia. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
10	A novel multiplex qPCR assay for detection of Plasmodium falciparum with histidine-rich protein 2 and 3 (pfhrp2 and pfhrp3) deletions in polyclonal infections. EBioMedicine, 2020, 55, 102757.	6.1	41
11	Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy. International Journal of Infectious Diseases, 2020, 95, 399-405.	3.3	16
12	Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the COVID-19 Pandemic?. American Journal of Tropical Medicine and Hygiene, 2020, 103, 558-560.	1.4	10
13	pfhrp2 and pfhrp3 Gene Deletions That Affect Malaria Rapid Diagnostic Tests for Plasmodium falciparum: Analysis of Archived Blood Samples From 3 African Countries. Journal of Infectious Diseases, 2019, 220, 1444-1452.	4.0	45
14	Artemisinin resistance-associated markers in Plasmodium falciparum parasites from the China-Myanmar border: predicted structural stability of K13 propeller variants detected in a low-prevalence area. PLoS ONE, 2019, 14, e0213686.	2.5	18
15	Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial. PLoS Medicine, 2019, 16, e1002762.	8.4	33
16	Molecular quantification of Plasmodium parasite density from the blood retained in used RDTs. Scientific Reports, 2019, 9, 5107.	3.3	15
17	Plasmodium -associated changes in human odor attract mosquitoes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4209-E4218.	7.1	105
18	Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity. Scientific Reports, 2018, 8, 10097.	3.3	14

#	Article	IF	Citations
19	Global analysis of Plasmodium falciparum histidine-rich protein-2 (pfhrp2) and pfhrp3 gene deletions using whole-genome sequencing data and meta-analysis. Infection, Genetics and Evolution, 2018, 62, 211-219.	2.3	40
20	Contribution of Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, Indonesia. Journal of Infectious Diseases, 2017, 215, 1148-1155.	4.0	84
21	Plasmodium falciparum parasites with histidine-rich protein 2 (pfhrp2) and pfhrp3 gene deletions in two endemic regions of Kenya. Scientific Reports, 2017, 7, 14718.	3.3	85
22	Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malaria Journal, 2016, 15, 36.	2.3	54
23	Alternatively spliced transcripts and novel pseudogenes of the Plasmodium falciparum resistance-associated locus pfcrt detected in East African malaria patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 116-123.	3.0	14
24	Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb. PLoS Neglected Tropical Diseases, 2015, 9, e0004068.	3.0	19
25	Directional Selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu Loci of Plasmodium falciparum in Kenyan Children Treated With ACT. Journal of Infectious Diseases, 2014, 210, 2001-2008.	4.0	108
26	Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malaria Journal, 2013, 12, 320.	2.3	36
27	Residual Plasmodium falciparum Parasitemia in Kenyan Children After Artemisinin-Combination Therapy Is Associated With Increased Transmission to Mosquitoes and Parasite Recurrence. Journal of Infectious Diseases, 2013, 208, 2017-2024.	4.0	109
28	The Polymorphic Linker Domain ofpfmdr1Is Associated with Resistance-Conferring Mutations in Plasmodium falciparum Populations from East and West Africa. Antimicrobial Agents and Chemotherapy, 2013, 57, 4595-4598.	3.2	3
29	Malaria Transmission After Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine: A Randomized Trial. Journal of Infectious Diseases, 2013, 207, 1637-1645.	4.0	99
30	HIV-Positive Nigerian Adults Harbor Significantly Higher Serum Lumefantrine Levels than HIV-Negative Individuals Seven Days after Treatment for Plasmodium falciparum Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 4146-4150.	3.2	10
31	Extended malaria parasite clearance time in African children following artemisinin-combination therapy enhances transmission to Anopheles mosquitoes. Malaria Journal, 2012, 11, O20.	2.3	1
32	Defining Plasmodium falciparum Treatment in South West Asia: A Randomized Trial Comparing Artesunate or Primaquine Combined with Chloroquine or SP. PLoS ONE, 2012, 7, e28957.	2.5	13
33	Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan. Malaria Journal, 2011, 10, 171.	2.3	17
34	Amodiaquine Resistance in Plasmodium falciparum Malaria in Afghanistan Is Associated with the pfcrt SVMNT Allele at Codons 72 to 76. Antimicrobial Agents and Chemotherapy, 2010, 54, 3714-3716.	3.2	72
35	Measuring the efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of parasite clearance. Malaria Journal, 2010, 9, 312.	2.3	61
36	Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates. Malaria Journal, 2010, 9, 68.	2.3	38